ProfileGDS5678 / 1436500_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 31% 28% 34% 29% 29% 26% 26% 28% 28% 29% 28% 28% 28% 28% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7455431
GSM967853U87-EV human glioblastoma xenograft - Control 22.6432228
GSM967854U87-EV human glioblastoma xenograft - Control 32.784334
GSM967855U87-EV human glioblastoma xenograft - Control 42.6113929
GSM967856U87-EV human glioblastoma xenograft - Control 52.6080829
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6640926
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6404926
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.6177728
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6263128
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6385129
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6303128
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6026828
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6417528
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6377428